1. Pink Sheet

Sunset Begins For Roche's Herceptin As Amgen/Allergan Biosimilar Launches

 
• By Jessica Merrill

Amgen and Allergan launched the first US biosimilar for Roche's Herceptin – and the Swiss pharma's Avastin – at a 15% discount to the brand-name products' list prices. Infographic reviews Herceptin's past and its future competitors.

sunset
The sun may set for Roche's Herceptin sales as US biosimilars launch. • Source: Shutterstock

Amgen Inc. and Allergan PLC launched the first US biosimilars for Roche's Herceptin (trastuzumab) and Avastin (bevacizumab) on 18 July, also marking the first oncology biosimilar launches in the US.

The Pink Sheet reviewed Herceptin's rise and its coming fall in anticipation of near-term biosimilar product market entry, which wasn't expected until later this year or possibly in early 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics